From Clinician Network to Care Infrastructure: How Wheel Is Closing the DTP Gap

April 30, 2026

“Consumers expect faster, simpler ways to get treatment, and that shift isn’t slowing down. But building for access is different from building for the full patient journey. To do that well, you need clear standards, clinical independence, and accountability from the start. That’s what will define which models actually last.”

Michelle Davey, CEO, Wheel

OVERVIEW

Wheel HorizonTM is a complete virtual care infrastructure that enables pharmaceutical companies to deliver direct-to-patient programs, combining clinical operations, a 50-state licensed clinician network, a care enablement platform, and real-time data and insights.
Unlike point solutions that address a single step in the DTP journey, Wheel operates as end-to-end care infrastructure, supporting intake, clinical visits, e-prescribing, prior authorization, and longitudinal follow-up within a single compliant system.
By supporting both episodic and longitudinal care, Wheel enables pharma brands to move beyond one-time transactions and build sustained patient relationships across therapies and conditions.

Pharma knows how to reach patients. Decades of television advertising, digital campaigns, and disease awareness programs have made that clear.

The gap has been what happens next. Whether a patient can actually see a clinician, navigate cost and access, and ultimately start and stay on therapy.

For many patients, that sequence breaks down before care ever begins.

Direct-to-patient (DTP) models are beginning to close that gap. But recognizing the opportunity and operationalizing it are very different challenges. The DTP journey spans intake, clinical evaluation, prescribing, prior authorization, fulfillment, and follow-up. When those components are assembled across multiple vendors, the result is often fragmentation, compliance risk, siloed data, and a disjointed patient experience.

That is the gap Wheel was built to solve.

From clinician matching to full infrastructure

Wheel launched in 2018 as Enzyme Health, a virtual clinician marketplace connecting providers with digital health companies. While the marketplace solved for access to clinicians, it quickly became clear that access alone was not enough.

Clients needed a way to manage the full care experience, not just staff it.

In response, Wheel began building a more comprehensive system. Starting in 2019 and accelerating through the pandemic, the company developed a purpose-built virtual care infrastructure that integrated clinical operations, technology, and patient experience into a single platform, now known as Horizon.

This shift from marketplace to infrastructure reflects a broader evolution in virtual care. The challenge is no longer simply connecting patients and providers. It is designing a cohesive system that supports patients from first interaction through ongoing care.

For pharma, that distinction is critical. Rather than integrating multiple vendors across the patient journey, partners can access a unified system where clinical, operational, and technical layers are designed to work together, with compliance embedded throughout.

The pharma opportunity, and what makes it different

Today, pharma’s DTP strategies are evolving along two paths. Some organizations are building above-brand platforms that serve multiple therapies across a portfolio. Others are launching brand-specific programs tied to individual products. Wheel supports both models.

What distinguishes pharma from other sectors is the regulatory environment. Pharma cannot directly operate clinical care in the same way as a digital health company. The requirements around independence, promotion, and patient interaction are more stringent, and the risks of getting it wrong are higher.

As a result, the clinical layer must operate independently while remaining tightly integrated into the overall patient experience. Wheel’s infrastructure is designed to meet that need, providing a compliant, evidence-based care layer that sits alongside the brand without being controlled by it.

From awareness to access in a single flow

For patients, the impact of DTP is most visible at the moment of access.

Consider a patient experiencing a flare-up of a chronic condition. In a traditional system, that patient may wait weeks or months for an appointment, often without clarity on treatment options in the meantime. The delay introduces friction, uncertainty, and drop-off.

DTP compresses that timeline. A patient who has seen a campaign, researched their symptoms, and decided to explore treatment can move directly into a clinical interaction. Within minutes, they can connect with a licensed clinician, complete an intake, and, if appropriate, receive a prescription.

Reducing time to care improves access. But access alone does not define success.

Where longitudinal care changes the equation

Episodic care, such as treating an acute infection, is a well-established use case for virtual care. However, the more significant opportunity for pharma lies in longitudinal care.

In these programs, patients require ongoing prescriptions, follow-up, and clinical oversight. Conditions such as weight management, menopause, and other chronic or lifestyle-driven therapies depend on sustained engagement over time.

This is where DTP shifts from a transactional model to a care model.

With more than 7 million patient visits to date, Wheel has observed that when patients enter through a convenient access point, they are more likely to engage in broader, ongoing care. What begins as a single interaction can evolve into a longer-term relationship, particularly when the experience is cohesive and easy to navigate.

In this model, the value is not defined by a single prescription. It is defined by continuity, adherence, and patient outcomes over time.

Infrastructure that scales, data that improves over time

As DTP programs mature, another layer of value emerges: data.

Because the entire patient journey is captured within a single system, Wheel’s platform generates real-time visibility into how patients move through care. This includes where patients drop off, how they progress through intake, how demographics influence engagement, and how different program elements affect outcomes.

This data is de-identified, aggregated, and surfaced back to pharma partners as actionable insight.

Unlike traditional claims data, which is delayed and limited in scope, DTP data provides immediate feedback. Pharma teams can use these insights to refine targeting, optimize pricing and access strategies, and improve program performance over time.

In this way, DTP becomes more than an access channel. It becomes a learning system.

Clinical infrastructure as competitive advantage

For pharma brands evaluating DTP strategies, the question is no longer whether to participate, but how to do so effectively.

Running a virtual visit is not the differentiator. Sustaining a patient relationship, maintaining clinical integrity, and continuously improving the program are what define long-term success.

This requires:

Evidence-based clinical protocols
Independent prescribing and clear separation between brand and care decisions
Secure, compliant infrastructure
The ability to capture and act on data across the patient journey

Patients engaging through DTP are not simply receiving prescriptions. They are entering a care experience that can support adherence, surface unmet needs, and extend engagement beyond a single interaction.

Delivering that experience consistently, and at scale, requires infrastructure that most pharma organizations cannot build independently.

That is the gap Wheel was designed to close.

Wheel is a DiMe partner and participant in DiMe’s direct-to-patient strategies project. Learn more at Wheel.com.